113 related articles for article (PubMed ID: 34504148)
1. Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort.
Lithgow K; Venkataraman H; Hughes S; Shah H; Kemp-Blake J; Vickrage S; Smith S; Humphries S; Elshafie M; Taniere P; Diaz-Cano S; Dasari BVM; Almond M; Ford S; Ayuk J; Shetty S; Shah T; Geh I
Sci Rep; 2021 Sep; 11(1):17947. PubMed ID: 34504148
[TBL] [Abstract][Full Text] [Related]
2. Expression and clinical value of CXCR4 in high grade gastroenteropancreatic neuroendocrine neoplasms.
Pang C; Li Y; Shi M; Fan Z; Gao X; Meng Y; Liu S; Gao C; Su P; Wang X; Zhan H
Front Endocrinol (Lausanne); 2024; 15():1281622. PubMed ID: 38524630
[TBL] [Abstract][Full Text] [Related]
3. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.
Bellizzi AM
Surg Oncol Clin N Am; 2020 Apr; 29(2):185-208. PubMed ID: 32151355
[TBL] [Abstract][Full Text] [Related]
4. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.
Sevilla I; Segura Á; Capdevila J; López C; García-Carbonero R; Grande E;
BMC Cancer; 2016 Nov; 16(1):858. PubMed ID: 27821081
[TBL] [Abstract][Full Text] [Related]
5. Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.
Pavel M; Lahner H; Hörsch D; Rinke A; Denecke T; Koch A; Regnault B; Helbig D; Hoffmanns P; Raderer M
Oncologist; 2024 May; 29(5):e643-e654. PubMed ID: 38206830
[TBL] [Abstract][Full Text] [Related]
6. Correlation of Ki-67 indices from biopsy and resection specimens of neuroendocrine tumours.
Barnes J; Johnson SJ; French JJ
Ann R Coll Surg Engl; 2017 Mar; 99(3):193-197. PubMed ID: 27490982
[TBL] [Abstract][Full Text] [Related]
7. Site-specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany.
Grundmann N; Voigtländer S; Hakimhashemi A; Pape UF; Meyer M; Müller-Nordhorn J
Cancer Med; 2023 Oct; 12(19):19949-19958. PubMed ID: 37737059
[TBL] [Abstract][Full Text] [Related]
8. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
Kulke MH; Benson AB; Dasari A; Huynh L; Cai B; Totev T; Roesner N; Duh MS; Neary MP; Maurer VE; Shih BE; Dagohoy CG; Chan J; Bergsland EK
Oncologist; 2019 Aug; 24(8):1056-1065. PubMed ID: 30606883
[TBL] [Abstract][Full Text] [Related]
9. Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort.
Papantoniou D; Grönberg M; Thiis-Evensen E; Sorbye H; Landerholm K; Welin S; Tiensuu Janson E
Endocr Relat Cancer; 2023 Mar; 30(3):. PubMed ID: 36629395
[TBL] [Abstract][Full Text] [Related]
10. Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms.
Pulvirenti A; Raj N; Cingarlini S; Pea A; Tang LH; Luchini C; Chou JF; Grego E; Marinova I; Capanu M; Landoni L; Scarpa A; Allen PJ; Klimstra DS; Reidy-Lagunes DL
Pancreas; 2021 Feb; 50(2):138-146. PubMed ID: 33565789
[TBL] [Abstract][Full Text] [Related]
11. Multicenter Analysis of Presacral Neuroendocrine Neoplasms-Clinicopathological Characterization and Treatment Outcomes of a Rare Disease.
Matrood S; Apostolidis L; Schrader J; Krug S; Lahner H; Ramaswamy A; Librizzi D; Kender Z; Kröcher A; Kreutzfeldt S; Gress TM; Rinke A
Front Endocrinol (Lausanne); 2021; 12():709256. PubMed ID: 34690926
[TBL] [Abstract][Full Text] [Related]
12. Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.
Hinterleitner M; Pfeiffer R; Trautwein NF; Sipos B; Singer S; Nadalin S; Königsrainer A; Lauer UM; la Fougère C; Zender L; Hinterleitner C
Front Endocrinol (Lausanne); 2023; 14():1285529. PubMed ID: 38260136
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms.
Morken S; Langer SW; Sundlöv A; Vestermark LW; Ladekarl M; Hjortland GO; Svensson JB; Tabaksblat EM; Haslerud TM; Assmus J; Detlefsen S; Couvelard A; Perren A; Sorbye H
Br J Cancer; 2023 Dec; 129(12):1930-1939. PubMed ID: 37872405
[TBL] [Abstract][Full Text] [Related]
14. HepPar1 and GATA-3 Expression in Neuroendocrine Neoplasms: A Potential Trap for Pathologic Diagnosis.
Xu L; Yu G; Jiang L; Song X; Qu G; Luo J; Cai L
Appl Immunohistochem Mol Morphol; 2023 Nov-Dec 01; 31(10):668-672. PubMed ID: 37751245
[TBL] [Abstract][Full Text] [Related]
15. Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites.
Sun TY; Zhao L; Van Hummelen P; Martin B; Hornbacker K; Lee H; Xia LC; Padda SK; Ji HP; Kunz P
Endocr Relat Cancer; 2022 Dec; 29(12):665-679. PubMed ID: 36165930
[TBL] [Abstract][Full Text] [Related]
16. Personalized treatment of well-differentiated gastric neuroendocrine tumors based on clinicopathological classification and grading: A multicenter retrospective study.
Huang J; Liu H; Yang D; Xu T; Wang J; Li J
Chin Med J (Engl); 2024 Mar; 137(6):720-728. PubMed ID: 38384175
[TBL] [Abstract][Full Text] [Related]
17. PITX2 as a Sensitive and Specific Marker of Midgut Neuroendocrine Tumors: Results from a Cohort of 1157 Primary Neuroendocrine Neoplasms.
Grass A; Kasajima A; Foersch S; Kriegsmann M; Brobeil A; Schmitt M; Wagner D; Poppinga J; Wiese D; Maurer E; Kirschbaum A; Muley T; Winter H; Rinke A; Gress TM; Kremer M; Evert M; Märkl B; Quaas A; Eckstein M; Tschurtschenthaler M; Klöppel G; Denkert C; Bartsch DK; Jesinghaus M
Mod Pathol; 2024 Apr; 37(4):100442. PubMed ID: 38309431
[TBL] [Abstract][Full Text] [Related]
18. Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort.
Panzuto F; Andrini E; Lamberti G; Pusceddu S; Rinzivillo M; Gelsomino F; Raimondi A; Bongiovanni A; Davì MV; Cives M; Brizzi MP; Persano I; Zatelli MC; Puliafito I; Tafuto S; Campana D
J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610840
[No Abstract] [Full Text] [Related]
19. Can Ki-67 predict radiotherapy response in neuroendocrine tumors? Retrospective analysis of a monocentric series of patients.
Zerini D; Rotondi M; Volpe S; Pisa E; Frigo E; Pedone C; Flospergher M; Bagnardi V; Frassoni S; Fodor CI; Spada F; Fazio N; Alterio D; Jereczek-Fossa BA
Tumori; 2023 Oct; 109(5):504-510. PubMed ID: 36942401
[TBL] [Abstract][Full Text] [Related]
20. Management of Small Bowel Neuroendocrine Tumours: 10 Years' Experience at a Tertiary Referral Centre.
Clift AK; Drymousis P; von Roon A; Humphries A; Goldin R; Bomanji J; Leaman S; Wasan H; Habib N; Frilling A
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
